Printer Friendly

Synthesis, structural characterization, and biological activity studies of Ni(II) and Zn(II) complexes.

1. Introduction

Metal complexes of O, S, and N containing Schiff bases have been the subject of current and growing interest because it has wide range of pharmacological activities [1]. In particular Schiff bases with 2-amino thiophenol, 2-amino phenol, 2amino benzoic acid, and 2-amino 3-hydroxy pyridine exhibit various biological activities such as antimicrobial activity, protein tyrosine phosphatases inhibition, and nuclease activity [2, 3]. Several aromatic amine Schiff bases have been investigated but few works deal with chromone skeleton derivatives. Chromones are a group of naturally occurring compounds that are ubiquitous in nature especially in plants. Molecules containing the chromone skeleton have extensive biological applications including antimycobacterial, antifungal, anticancer, antioxidant, antihypertensive, and antiinflammatory applications and tyrosinase and protein kinase Cinhibitors 4-13].

DNA plays an important role in the life process since it contains all the genetic information for the cellular function. However, DNA is the primary intracellular target of anticancer drugs, damaged under various conditions such as interactions with some small molecules, which cause DNA damage in cancer cells blocking the division of cancer cells and resulting in cell death. Metal complexes such as cobalt, nickel, copper, and zinc with Schiff base ligands have shown excellent binding and cleavage activities [14-16]. There is substantial literature supporting the DNA binding studies of chromone Schiff bases and their metal complexes [17-19]. Compounds showing the properties of effective binding as well as cleaving double stranded DNA under physiological conditions are of great importance since these could be used as diagnostic agents in medicinal and genomic research.

Fluorescent transition metal centres are particularly attractive moieties because they often possess distinctive electrochemical or photophysical properties, thus enhancing the functionality of the binding agent [20].

In previous papers we presented synthesis, detailed characterization, and biological activity studies of 3-formyl chromone Schiff bases such as 3-((2-hydroxy phenylimino)methyl)-4H-chromen-4-one ([HL.sub.1]),2-((4-oxo-4H-chromen-3-yl)methylneamino)benzoic acid (HL2), 3-((3-hydroxypy ridin-2-ylimino)methyl)-4H-chromen-4-one (HL3), 3-((2mercapto phenylimino)methyl)-4H-chromen-4-one (HL4), and their Cu(II), Co(II), and Pd(II) complexes [21-23]. The present paper deals with the synthesis, characterization of Ni(II) and Zn(II) complexes of 3-formyl chromone Schiff bases (HLX, HL2, HL3, and HL4), and various biological activity studies, that is, antimicrobial, antioxidant, and nematicidal activities and cytotoxicity and DNA cleavage.

2. Experimental

2.1. Materials and Physical Measurements. All the chemicals used were of analytical grade and procured from Spectrochem Pvt. Ltd., Mumbai, India. 3-Formyl chromone was synthesized according to the literature [24].

The elemental analysis of carbon, hydrogen, nitrogen, and sulphur contents was performed using Perkin Elmer CHNS analyser. Molar conductance of the complexes was measured using a Digisun conductivity meter in DMF. The electronic absorption spectra of the complexes were recorded on JASCO V-670 Spectrophotometer in the wavelength region of 250-1400 nm in the solid state. The FTIR spectra of the complexes were recorded on Tensor 2 FTIR spectrophotometer in the region of 4000-400 [cm.sup.-1] using KBr disc. The magnetic susceptibilities of Ni(II) complexes were measured with a Sherwood scientific balance. Diamagnetic corrections were calculated from Pascal's constants. The magnetic moment values were calculated using the relation [[mu].sub.eff] = 2.83 [([[chi].sub.m]T).sup.1/2] B.M. Thermal studies of the complexes were carried out on a Perkin Elmer diamond TGA instrument at a heating rate of 10[degrees]C and nitrogen flow rate of 20 mL/min. The fluorescence spectra of the complexes were recorded on Fluorolog FL3-11 spectrofluorometer. The X-ray patterns of the complexes were recorded on Xpert-Pro X-ray diffractometer with Cu Ka radiation ([lambda] = 1.5406 [Angstrom]). The diffraction data are integrated by using the Nakamuta program. Scanning electron micrograph (SEM) of the complexes was obtained in a Hitachi S-520 electron microscope at an accelerated voltage of 15 kV.

2.2. Synthesis of Ligands. All the Schiff base ligands [HL.sub.1], [HL.sub.2], [HL.sub.3], and [HL.sub.4] (Figure 1) were prepared according to the literature methods [21, 25,26].

2.3. Synthesis of Metal Complexes. The ligands (2mM) and metal acetates (Ni[([CH.sub.3]COOH).sub.2] x 4[H.sub.2]O and Zn[([CH.sub.3] COOH).sub.2] x 2[H.sub.2]O) (1 mM) were dissolved in methanol. The mixtures were stirred at room temperature for 2-3 h; various colour precipitates were separated from the solution by suction filtration, purified by washing several times with methanol, and dried for 12 h in vacuum.

2.4. Antimicrobial Activity. In vitro antimicrobial activity of the metal complexes towards the bacteria Proteus vulgaris, Klebsiella pnuemoniae, Staphylococcus aureus, and Bacillus subtili and fungi Candida albicans was carried out using disc diffusion method. The antibiotics kanamycin and clotrimazole are the standards for antibacterial and antifungal activity studies. Standard inoculum, 1-2 x [10.sup.7] cfu/mL 0.5 Mc Farland standards [27], was introduced onto the surface of sterile nutrient agar plate and evenly spread by using a sterile glass spreader. Sterile antibiotic discs (6 mm in diameter, prepared using Whatmann number 1 paper) were placed over the nutrient agar medium. Each disc was spread by 100 [micro]g of the compounds (initially dissolved in DMSO). The plates were incubated with bacterial cultures for 24 h at 37[degrees]C and fungal cultures at 25[degrees]C for 48 h. The activity of the compounds was determined by measuring the diameter of inhibition zone in "millimetres" and compared with standard antibiotics. DMSO (which has no activity) and standard antibiotics were used as negative and positive controls for antimicrobial activity studies. The activity results are calculated as a mean of triplicates.

Minimum inhibitory concentrations (MIC) of the complexes which showed antimicrobial activity were determined using the literature method [28]. All the compounds that were diluted within the range of 100-10 [micro]g/mL were mixed in nutrient broth and 0.1 mL of active inoculums was added to each tube. The tubes were incubated aerobically at 37[degrees]C for bacteria and 25[degrees]C for fungi up to 24 h. The lowest concentration of the compound that completely inhibited bacterial growth (no turbidity) in comparison to control was regarded as MIC.

2.5. Nematicidal Activity. Root knot nematode, Meloidogyne incognita, is major plant parasitic nematodes affecting quantity and quality of the crop production in many annual and perennial crops. Meloidogyne nematode can develop galls and lesions in the roots, thereby causing stunted growth of the plants. Some of the chemicals can be used to control nematodes [29].

Nematicidal activity of the complexes was carried out on Meloidogyne incognita. Fresh egg masses of Meloidogyne incognita are collected from stock culture maintained on tomato (Lycopersicon esculentum) root tissues and kept in water for egg hatching. The eggs suspensions were poured on a cotton wool filter paper and incubated at 30[degrees] C to obtain freshly hatched juveniles (J2). Juveniles collected within 48 h were used for screening nematicidal activity of the compounds.

The compounds were initially dissolved in dimethyl sulfoxide (DMSO) and then in distilled water to make dilutions of 250, 150, and 50 [micro]g/mL. Experiments were performed under laboratory conditions at 30[degrees]C. About 100 freshly hatched second stage juveniles were suspended in 5 mL of each diluted compound and incubated. Distilled water with nematode larvae was taken as control. The dead nematodes were observed under an inverted binocular microscope. After an incubation of 24 and 48 h, percentage of mortality was calculated. Nematodes were considered dead if they did not move when probed with a fine needle [30].

2.6. DPPH Radical Scavenging Activity. The free radical scavenging activities of the metal complexes were determined by using DPPH free radical scavenging method according to the literature 31]. DPPH is a stable free radical containing an odd electron in its structure and usually utilized for detection of the radical scavenging activity in chemical analysis. In the spectrophotometric assay the ability to scavenge the stable free radical DPPH is measured by decrease in the absorbance at 517 nm. Each compound was dissolved in methanol (10 mg/10 mL) and it was used as stock solution. From the stock solutions, 1 mL of each compound solution with different concentrations (0.25 [micro]g-1.00 [micro]g) was added to the 3mL of methanolic DPPH (0.004%) solution. After 30 min, the absorbance of the test compounds was taken at 517 nm using UV-VIS spectrophotometer. BHT was used as standard, DPPH solution was used as control without the test compounds, and methanol was used as blank. The percentage of scavenging activity of DPPH free radical was measured by using the following formula:

Scavenging activity (%) = [([A.sub.o] - [A.sub.i]/[A.sub.o]) x 100, (1)

where [A.sub.o] is the absorbance of the control and [A.sub.i] is the absorbance of the sample.

2.7. Cytotoxic Activity. The human breast carcinoma cell line (MCF-7), human colon carcinoma cell line (COLO 205), and murine microphage cell line (Raw 264.7) were obtained from the National Centre for Cell Science (NCCS), Pune, and grown in Dulbecco's Modified Eagles Medium (DMEM) containing 10% fetal bovine serum (FBS), amphotericin (3 [micro]g/mL), gentamycin (400 [micro]g/mL), streptomycin (250 [micro]g/mL), and penicillin (250 units/mL) in a carbon dioxide incubator at 5% C[O.sub.2]. About 700 cells/well were seeded in 96-well plate using culture medium; the viability was tested using trypan blue dye with help of haemocytometer and 95% of viability was confirmed. After 24 h, the new medium with compounds in the concentration of 100,10, and 1 [micro]g/mL were added at respective wells and kept in incubation for 48 h. After incubation MTT assay was performed.

2.7.1. MTT Assay. After 48 h of the drug treatment the medium was changed again for all groups and 10 [micro]L of MTT (5 mg/mL stock solution) was added and the plates were incubated for an additional 4 h. The medium was discarded and the formazan blue, which was formed in the cells, was dissolved with 50 [micro]L of DMSO. The optical density was measured on microplate spectrophotometer at a wavelength of 570 nm. The percentage of cell inhibition was calculated by using the following formula [32]:

%Growth inhibition = 100 - ([A.sub.i]/[A.sub.o]) x 100, (2)

where [A.sub.i] is the absorbance of the sample and [A.sub.0] is the absorbance of the control. [IC.sub.50] values were determined using Graph Pad Prism software.

2.8. DNA Cleavage Activity. The DNA cleavage activity of metal complexes was monitored by agarose gel electrophoresis. pUC19 plasmid was cultured, isolated, and used as DNA for the experiment. Test samples (1 mg/mL) were prepared in DMF. 25 [micro]g of the test samples was added to the isolated plasmid and incubated for 2h at 37[degrees] C. After incubation, 30 [micro]L of plasmid DNA sample mixed with bromophenol blue dye (1: 1) was loaded into the electrophoresis chamber wells along with the control DNA, 5 M FeS[O.sub.4] (treated with DNA), and standard DNA marker containing TAE buffer (4.84 g Tris base, pH 8.0, 0.5 M EDTA/1L). Finally, it was loaded on to an agarose gel and electrophoresed at 50 V constant voltage up to 30 min. After the run, gel was removed and stained with 10.01 [micro]g/mL ethidium bromide and image was taken in Versadoc (Biorad) imaging system. The results were compared with standard DNA marker. The same procedure was followed in the presence of [H.sub.2][O.sub.2] also.

3. Results and Discussion

All the Ni(II) complexes were colored, stable, and nonhygroscopic in nature. The complexes are insoluble in common organic solvents but soluble in DMF and DMSO. The elemental analysis showed that the complexes have 1 : 2 stoichiometry of the type [M[([L.sub.1-4]).sub.2]] x n[H.sub.2]O, where L stands for singly deprotonated ligands. Molar conductance of the complexes was measured in DMF. The conductance values, which are presented in the Table 1, indicate the nonelectrolytic nature of the complexes [33].

3.1. Determination of the Metal Content of the Complexes. Known amount (0.150 g) of complexes was decomposed with concentrated nitric acid. This process was repeated till the organic part of the complexes got completely lost. The excess nitric acid was expelled by evaporation with concentrated sulphuric acid. The Ni(II) and Zn(II) contents of the complexes were determined as per the procedure available in the literature [34].

3.2. FTIR Spectra. The FTIR spectra of the complexes are compared with those of the ligands in order to determine the coordination sites that may involve in chelation. The position and/or the intensities of bands are expected to be changed while the coordination. The most important IR bands of the metal complexes with probable assignments are given in Table 2. The Schiff base ligands showing a band around 1650-1620 [cm.sup.-1] is assigned to the (C=O) group of the chromone system. Upon complexation the [nu](C=O) group is shifted to 20-35 [cm.sup.-1] lower wavenumber region 35]. The ligands show the most characteristic [nu](C=N) bands in the region 1605-1563 [cm.sup.-1]. In the spectra of their corresponding metal complexes, this band appears at 25-45 [cm.sup.-1] to lower wavenumber region indicating the coordination of the azomethine nitrogen atom to the metal ion [36]. A broad band appeared in [HL.sub.1] and [HL.sub.3] at 3241 and 3246 [cm.sup.-1], respectively, and is attributed to the [nu](O-H) group. The absence of the band in the spectra of their corresponding metal complexes is due to the involvement of oxygen atom of (OH) group coordination to the metal ion. In [HL.sub.2] ligand, a strong band appeared at 1365 [cm.sup.-1] and is due to the [nu](C-O) of carboxylic group. In its metal complexes it is shifted to 1847 [cm.sup.-1] lower wavenumber region [37]. Since SH stretching frequency band is very weak, the peak corresponding to SH is not clearly observed in the case of [HL.sub.4] ligand [38]. Presence of band around 3400 [cm.sup.-1] in all the complexes is the indication of water molecules present in the complexes. The presence of oxygen and nitrogen in the coordination sphere is further confirmed by the presence of [nu](M-N) and [nu](M-O) bands at 400-600 [cm.sup.-1] region. The FTIR results show that all Schiff base ligands act as tridentate chelating ligands.

3.3. Electronic Spectra and Magnetic Moments. The electronic absorption spectra of the Schiff base metal complexes in solid state were recorded at room temperature and the band positions of the absorption maxima, band assignments, ligand field parameters, and magnetic moment values are listed in Table 3. The electronic spectra of [Ni[([L.sub.4]).sub.2]] x [H.sub.2]O and [Zn[([L.sub.4]).sub.2]] x [H.sub.2]O complexes are depicted in Figure 2. The electronic spectra of Ni(II) complexes displayed three absorption bands in the range 8000-9000,14000-16000, and 20000-24000 [cm.sup.-1]. Thus, these bands may be assigned to the three spin allowed transitions [sup.3][A.sub.2g] (F) [right arrow] [sup.3][T.sub.2g] (F) ([[nu].sub.1]), [sup.3][A.sub.2g] (F) [right arrow] [sup.3][T.sub.1g] (F) ([[nu].sub.2]), and [sup.3][A.sub.2g] (F) [right arrow] [sup.3][T.sub.1g] (P) ([[nu].sub.3]), respectively, characteristic of octahedral geometry. The values of transition ratio [[nu].sub.2]/[[nu].sub.1] and [beta] lie in the range of 1.70-1.80 and 0.89-0.95, respectively, providing further evidence for octahedral geometry of Ni(II) complexes [39]. The B values for the complexes are lower than the free ion value, thereby indicating orbital overlap and delocalisation of d-orbitals. The [beta]-values obtained are less than unity suggesting the covalent character of the metal-ligand bonds. All Ni(II) complexes are paramagnetic and the magnetic movement values at room temperature are in the range of 2.91-3.25 B.M which is well agreed with the reported octahedral Ni(II) complexes [40]. All Zn(II) complexes showed two bands around 25000 and 30000 [cm.sup.-1] and are attributed to the n [right arrow] [[pi].sup.*] and [pi] [right arrow] [[pi].sup.*] transitions, respectively. Zn(II) complexes that are in [d.sup.10] configuration are diamagnetic and do not show any d-d transitions.

3.4. Thermal Analysis. The thermogravimetric analysis (TGA) of the metal complexes was carried out within the temperature range from room temperature to 1000[degrees]C. The TG-DTA graphs of [Ni[([L.sub.4]).sub.2]] and [Zn[([L.sub.4]).sub.2]] x [H.sub.2]O complexes are given in Figure 3. The TGA data and their assignments of all the metal complexes are listed in Table 4. Metal complexes decompose gradually with formation of respective metal oxides. The TG graphs of [Ni[([L.sub.2]).sub.2]] x [H.sub.2]O, [Ni[([L.sub.3]).sub.2]] x [H.sub.2]O, [Zn[([L.sub.1]).sub.2] x [H.sub.2]O, and [Zn[([L.sub.4]).sub.2]] x [H.sub.2]O complexes decompose in two to three steps. The first step corresponds to the loss of lattice water molecule in the temperature range between 30 and 140[degrees]C with a weight loss of 2-3%. In the second and third steps, the total loss of ligand molecules was observed in the temperature range between 160 and 850[degrees]C leaving behind metal oxide as residue. The thermal decomposition of remaining metal complexes ([Ni(L1)2], [Ni[([L.sub.4]).sub.2]] [Zn[([L.sub.2]).sub.2]] and [Zn[([L.sub.3]).sub.2]]) occurs in two to three steps. Upon starting heating, these metal complexes losses of the organic moieties of Schiff base ligands were observed in two to three successive steps within the temperature range of 150-850[degrees]C. In all the complexes the final mass loss is due to the formation of metal oxides as residue.

On the basis of all spectral data (elemental analysis, FTIR, electronic spectra, and thermal analysis), the suggested structures of the complexes are shown in Figure 4.

3.5. Powder XRD and SEM Studies. Single crystals of the complexes could not be obtained because of their insolubility in most organic solvents, hence, the powder diffraction data were obtained for structural characterization. The powder XRD patterns of all metal complexes were recorded in the range 2[theta] = 10-50[degrees]. The powder XRD pattern of [Ni[([L.sub.1]).sub.2]] and [Zn[([L.sub.1]).sub.2]] x [H.sub.2]O are presented in Figure 5. Observed and calculated powder XRD data of [Ni[([L.sub.1]).sub.2]] and [Zn[([L.sub.1]).sub.2]] x [H.sub.2]O are given in Tables 5(a) and 5(b). Unit cell parameters were found by using trial and error methods. All complexes are triclinic with different unit cell parameters. All metal complexes display sharp crystalline peaks except [Zn[([L.sub.2]).sub.2]] and [Zn[([L.sub.4]).sub.2]]-[H.sub.2]O; these two complexes do not exhibit welldefined crystalline peaks due to their amorphous nature. The unit cell parameters of metal complexes are as follows: [Ni[([L.sub.1]).sub.2]]: a = 8.80 [Angstrom], b = 8.52 [Angstrom], c = 7.50 [Angstrom], [alpha] = 99.93[degrees], [beta] = 116.71[degrees], [gamma] = 90.01[degrees], and V = 562 [([Angstrom]).sup.3]; [Ni[([L.sub.2]).sub.2]] x [H.sub.2]O: a = 8.24 [Angstrom], b = 9.24 [Angstrom], c = 7.32 [Angstrom] [alpha] = 104.12[degrees], [beta] = 124.44[degrees], [gamma] = 98.04[degrees], and V = 557 [([Angstrom]).sup.3]; [Ni[([L.sub.3]).sub.2]] x [H.sub.2]O: a = 9.40 [Angstrom], b = 9.20 [Angstrom], c = 8.46 [Angstrom], [alpha] = 97.45[degrees], [beta] = 107.38[degrees], [gamma] = 91.45[degrees], and V = 731 [([Angstrom]).sup.3]; [Ni[([L.sub.4]).sub.2]]: a = 7.73 [Angstrom], b = 8.24 [Angstrom], c = 8.49 [Angstrom], [alpha] = 98.30[degrees], [beta] = 104.76[degrees], [gamma] = 90.55[degrees], and V = 540 [([Angstrom]).sup.3]; [Zn[([L.sub.3]).sub.2]] x [H.sub.2]O: a = 9.60 [Angstrom], b = 9.94 [Angstrom], c = 8.89 [Angstrom], [alpha] = 102.34[degrees], [beta] = 109.69[degrees], [gamma] = 93.94[degrees], and V = 848 [([Angstrom]).sup.3]; [Zn[([L.sub.3]).sub.2]]: a = 8.76 [Angstrom], b = 9.04 [Angstrom], c = 8.61 [Angstrom], [alpha] = 105.78[degrees], [beta] = 103.02[degrees], [gamma] = 90.21[degrees], and V = 682 [([Angstrom]).sup.3]. The average crystallite sizes (D) of the metal complexes are calculated from the Scherrer formula [41]:

D = 0.9[lambda]/[beta] cos [theta], (3)

where [lambda] is the X-ray wavelength, [beta] is the full width at half maximum of prominent intensity peak, and [theta] is the diffraction angle. The [Ni[([L.sub.4]).sub.2]], [Ni[([L.sub.2]).sub.2]] x [H.sub.2]O, [Ni[([L.sub.3]).sub.2]] x [H.sub.2]O, [Ni[([L.sub.4]).sub.2]], [Zn[([L.sub.1]).sub.2]] x [H.sub.2]O, and [Zn[([L.sub.3]).sub.2]] complexes have an average crystallite size of 70,17,16, 27, 42, and 53 nm, respectively, suggesting that the complexes are in nanocrystalline phase.

The SEM (Scanning Electron Microscope) is used to evaluate the morphology and particle size of the compounds. The SEM photographs of [Ni[([L.sub.3]).sub.2]] x [H.sub.2]O and [Ni[([L.sub.4]).sub.2]] are shown in Figure 6. The SEM micrographs show the agglomerate particles of the complexes. In case of [Ni[([L.sub.3]).sub.2]] x [H.sub.2]O and [Ni[([L.sub.4]).sub.2]] complexes, some agglomerates appear to have tiny needles, while the other agglomerates appear to be of spherical plates like morphologies.

3.6. Fluorescence Spectra. The fluorescence characteristics of metal complexes were studied at room temperature in solid state. In metal complexes metal to ligand coordination may lead to significant changes of the fluorescence properties of the ligand, including increase or decrease of the intensity, emission wavelength shift, quenching of the fluorescence, or appearance of new emissions [42]. The fluorescence spectra of HL: ligand and its metal (Ni(II) and Zn(II)) complexes were depicted in Figure 7. The Ni(II) and Zn(II) complexes of HL: were characterised by emission bands around (522, 569) nm and (458, 644) nm, upon photo excitation at 453 and 357 nm, respectively. The Ni(II) complex of [HL.sub.2] exhibits emission bands at 449 and 524 nm. Zn(II) complex of HL2 does not show any emission spectra. The Ni(II) and Zn(II) complexes of [HL.sub.3] were characterised by an emission bands at (504, 570, and 668) and 419 nm, respectively. The Ni(II) and Zn(II) complexes of HL4 exhibit emission bands around 539 and 613 nm, respectively. From the results, red shift and quenching of the metal ions was observed in the case of ligands and its metal complexes.

3.7. Antimicrobial Activity. The minimum inhibitory concentrations (MIC) of the complexes compared with the ligands and standard drugs are listed in Table 6. The results indicate that the metal complexes displayed more antibacterial activity compared to the parent ligands under similar experimental conditions on same microorganisms except [Ni[([L.sub.2]).sub.2]][H.sub.2]O and [Zn[([L.sub.4]).sub.2]][H.sub.2]O complexes. The results indicate that the metal complexes displayed more antibacterial activity compared to the parent ligands under similar experimental conditions on same microorganisms except [Zn[([L.sub.4]).sub.2]][H.sub.2]O. However, [Ni[([L.sub.4]).sub.2]], [Ni[([L.sub.3]).sub.2]][H.sub.2]O, [Zn[([L.sub.2]).sub.2]] and [Zn[([L.sub.3]).sub.2]] complexes showed antifungal activity while the remaining complexes did not show any activity. However, [Ni[([L.sub.3]).sub.2]], [Ni[([L.sub.3]).sub.2]][H.sub.2]O, and [Zn[([L.sub.3]).sub.2]] complexes showed antifungal activity while the remaining complexes did not show any activity. Among all the metal complexes [Zn[([L.sub.3]).sub.2]] complex showed good activity against all bacteria and fungi strains. Increase in the activity of the complexes compared to that of ligands can be explained on the basis of Overtone's concept and Tweedy's chelation theory. The theory states that the polarity of the metal ion is reduced on complexation due to the partial sharing of its positive charge with donor groups. Consequently, the positive charge is delocalized over the whole ring, which causes the improved lipophilicity of the compound through cell membrane of the pathogen [43]. The negative results can be attributed either to the inability of the complexes to diffuse into the bacteria cell membrane and hence they become unable to interfere with its biological activity or they can diffuse and become inactivated by unknown cellular mechanism, that is, bacterial enzymes [44].

3.8. Nematicidal Activity. All complexes except [Ni[([L.sub.3]).sub.2]] [H.sub.2]O and [Zn[([L.sub.3]).sub.2]] showed very less nematicidal activity against Meloidogyne incognita. However, [Ni[([L.sub.3]).sub.2]][H.sub.2]O and [Zn[([L.sub.3]).sub.2]] complexes exhibited moderate activity indicating 47% and 51% mortality, respectively, after 48 h exposure in 250 [micro]g/mL concentration. However, the activity of the metal complexes depends on concentration and time, that is, activity was higher at high concentrations and increased with time.

3.9. DPPH Radical Scavenging Activity. The antioxidant activity of the complexes was tested by measuring their ability to donate an electron to the free radical compound DPPH, monitoring changes in absorption at 517 nm using UV-VIS spectrophotometer. [IC.sub.50] values were calculated and compared with the standard. [IC.sub.50] values of the metal complexes are tabulated in Table 7. All complexes showed very less activity except [Ni[([L.sub.3]).sub.2]], [Ni[([L.sub.4]).sub.2]], and [Zn[([L.sub.4]).sub.2]][H.sub.2]O complexes. Among all the complexes [Zn[([L.sub.4]).sub.2]][H.sub.2]O ([IC.sub.50] = 0.69 [micro]g/mL) complex exhibited comparable activity to that of standard drug BHT (butylated hydroxyl toluene) ([IC.sub.50] = 0.67 [micro]g/mL).

3.10. Cytotoxic Activity. The cytotoxicity of Schiffbase ligands and their metal complexes were carried out using MTT assay. [IC.sub.50] is employed to stand for the cytotoxicities of the compounds against the cancer cell lines; the smaller the [IC.sub.50] value in the same condition is, the higher the cell growth inhibitory potency. DMSO when used as control without test sample, it does not exhibit any cytotoxic activity against all cancer cell lines. Cis-platin is used as positive control and it showed the highest cytotoxicity. The [IC.sub.50] values were calculated after 48 h of incubation with compounds and are listed in Table 8. As shown in Table 8, all the ligands and their metal complexes showed lower cytotoxicity against selected cancer cell lines compared to the cis-platin. HL3 ligand showed enhanced activity against COLO 205 cell lines compared to all ligands and metal complexes ([IC.sub.50] = 15.2 [micro]g/mL). The lowest [IC.sub.50] values (33.1 and 22.6 [micro]g/mL) are observed for Zn(II) complex of HL3 ligand against raw and MCF-7 cell lines among all the ligands and metal complexes indicating its significant potency against two cancer cell lines. The results revealed that pyridine ring may be playing an important role in the cytotoxicity of the compounds.

3.11. DNA Cleavage Activity. pUC19 DNA was chosen for the DNA cleavage activity of the complexes. The studies were done using gel electrophoresis. Its naturally occurring supercoiled form (Form I) when nicked gives rise to an open circular relaxed form (Form II) and upon further cleavage results in the linear form (Form III). When subjected to gel electrophoresis, Form I migrates relatively faster while the nicked form (Form II) migrates slowly and linearized Form III migrates between Form I and Form II [45]. In the present study gel electrophoresis experiments were performed in the presence and absence of an oxidizing agent [H.sub.2][O.sub.2] to investigate the mechanism of nucleolytic activity of the complexes. The activity was greater for the complexes in the presence of [H.sub.2][O.sub.2]. Control (DNA alone) does not show activity (Figure 8(a)). When FeS[O.sub.4] is used as standard, it shows complete DNA cleavage. In the absence of [H.sub.2][O.sub.2] all complexes show partial nucleolytic activity. Probably this may be due to the redox behaviour of the metal ions. These results indicated the important role of the metal ions in cleavage studies. In the presence of [H.sub.2][O.sub.2], (Figure 8(b)) absence of marker bands was observed in all the complexes except [Ni[([L.sub.3]).sub.2]]-[H.sub.2]O and [Zn[([L.sub.3]).sub.2]]; [Zn[([L.sub.4]).sub.2]]-[H.sub.2]O complexes indicate the complete DNA cleavage activity. In the case of [Ni[([L.sub.3]).sub.2]]-[H.sub.2]O, [Zn[([L.sub.3]).sub.2]], and [Zn[([L.sub.4]).sub.2]]-[H.sub.2]O complexes a decrease in the intensity of bands was observed compared to the control. This is probably due to the partial cleavage of the DNA. The DNA cleavage activity of the complexes in the presence of [H.sub.2][O.sub.2] may be due to the reaction of hydroxy radicals with DNA. The general oxidative mechanisms of the DNA cleavage studies were reported by several research groups [46-48]. Many literature reports infer that the compound was to cleave the DNA; it can be concluded that the compound inhibits the growth of the pathogenic organism by cleaving the genome [49].

4. Conclusions

Ni(II) and Zn(II) complexes have been synthesized using 3formyl chromone Schiff bases and characterized by various analytical and spectral data. Based on the electronic spectra, magnetic moment, and elemental analysis data, octahedral geometry was proposed for Ni(II) and Zn(II) complexes. The well-defined crystalline and homogeneous nature of the metal complexes is observed from powder XRD and SEM analyses. The antimicrobial activity data has shown that [Zn(L3)2] complex displayed higher activity among all other metal complexes. The nematicidal activity of metal complexes revealed that [Ni[([L.sub.3]).sub.2]]-[H.sub.2]O and [Zn[([L.sub.3]).sub.2]] complexes showed moderate activity. [Zn[([L.sub.4]).sub.2]]-[H.sub.2]O complex exhibited greater antioxidant activity compared to the remaining metal complexes. All metal complexes exhibited considerable cytotoxic activity against Raw, MCF-7, and COLO 205 cell lines. The DNA cleavage studies of metal complexes showed more prominent activity in the presence of [H.sub.2][O.sub.2] compared to that in the absence of [H.sub.2][O.sub.2].

http://dx.doi.org/10.1155/2014/568741

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors wish to thank Dr. M.R.P. Reddy, CMET (Centre for the Materials for Electronic Technologies), Hyderabad, for providing TG facility. The authors are thankful to the Department of Biochemistry, SV University, Tirupathi, for antioxidant activity study, Vimta Labs Ltd., Hyderabad, for DNA cleavage studies, and PSG college of Pharmacy, Coimbatore, Tamilnadu, for anticancer activity studies. The authors also wish to thank the Ministry of Human Resource Development for granting the research fellowship to Kavitha Palakuri.

References

[1] N. K. Singh, A. Srivastava, A. Sodhi, and P. Ranjan, "In vitro and in vivo antitumour studies of a new thiosemicarbazide derivative and its complexes with 3d-metal ions," Transition Metal Chemistry, vol. 25, no. 2, pp. 133-140, 2000.

[2] N. Raman, K. Pothiraj, and T. Baskaran, "DNA interaction, antimicrobial, electrochemical and spectroscopic studies of metal(II) complexes with tridentate heterocyclic Schiff base derived from 2-methylacetoacetanilide" Journal of Molecular Structure, vol. 1000, no. 1-3, pp. 135-144, 2011.

[3] C. Yuan, L. Lu, Y. Wu et al., "Synthesis, characterization, and protein tyrosine phosphatases inhibition activities of oxovanadium(IV) complexes with Schiff base and polypyridyl derivatives," Journal of Inorganic Biochemistry, vol. 104, no. 9, pp. 978-986, 2010.

[4] Y. Li, Z.-Y. Yang, and J.-C. Wu, "Synthesis, crystal structures, biological activities and fluorescence studies of transition metal complexes with 3-carbaldehyde chromone thiosemicarbazone" European Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 5692-5701, 2010.

[5] Y. S. Shim, K. C. Kim, D. Y. Chi, K.-H. Lee, and H. Cho, "Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors," Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 15, pp. 2561-2563, 2003.

[6] K. M. Khan, N. Ambreen, U. R. Mughal, S. Jalil, S. Perveen, and M. I. Choudhary, "3-formylchromones: potential antiinflammatory agents," European Journal of Medicinal Chemistry, vol. 45, no. 9, pp. 4058-4064, 2010.

[7] G. Mhaske, P. Nilkanth, A. Auti, S. Davange, and S. Shelke, "Aqua medicated, microwave assisted, synthesis of Schiff bases and their biological evaluation," International Journal of Innovative Research in Science, Engineering and Technology, vol. 3, pp. 8156-8162, 2014.

[8] M. T. Hussain, N. H. Rama, and K. M. Khan, "A novel unusual isocoumarin derivative, 3H-Furo[3, 4-c] isochromene1, 5-dione," Letters in Organic Chemistry, vol. 7, no. 7, pp. 557560, 2010.

[9] A. A. Osowole, "Synthesis, characterization, in-vitro antibacterial and anticancer studies on some metal(II) complexes of (methylsulfanyl)chromenol Schiff base," Elixir Applied Chemistry, vol. 39, pp. 4827-4831, 2011.

[10] K. M. Khan, A. Ahmad, N. Ambreen et al., "Schiff bases of 3formylchromones as antibacterial, antifungal, and phytotoxic agents," Letters in Drug Design and Discovery, vol. 6, no. 5, pp. 363-373, 2009.

[11] S. Bhatnagar, S. Sahi, P. Kackar et al., "Synthesis and docking studies on styryl chromones exhibiting cytotoxicity in human breast cancer cell line," Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 16, pp. 4945-4950, 2010.

[12] A. Gomes, O. Neuwirth, M. Freitas et al., "Synthesis and antioxidant properties of new chromone derivatives," Bioorganic & Medicinal Chemistry, vol. 17, no. 20, pp. 7218-7226, 2009.

[13] L. Z. Piao, H. R. Park, Y. K. Park, S. K. Lee, J. H. Park, and

M. K. Park, "Mushroom tyrosinase inhibition activity of some chromones," Chemical and Pharmaceutical Bulletin, vol. 50, no. 3, pp. 309-311, 2002.

[14] S. A. Patil, S. N. Unki, A. D. Kulkarni, V. H. Naik, and P. S. Badami, "Synthesis, characterization, in vitro antimicrobial and DNA cleavage studies of Co(II), Ni(II) and Cu(II) complexes with ONOO donor coumarin Schiffbases," Journal of Molecular Structure, vol. 985, no. 2-3, pp. 330-338, 2011.

[15] F. Arjmand, F. Sayeed, and M. Muddassir, "Synthesis of new chiral heterocyclic Schiff base modulated Cu(II)/Zn(II) complexes: their comparative binding studies with CT-DNA, mononucleotides and cleavage activity," Journal of Photochemistry and Photobiology B: Biology, vol. 103, no. 2, pp. 166-179, 2011.

[16] C. N. Sudhamani, H. S. B. Naik, T. R. R. Naik, and M. C. Prabhakara, "Synthesis, DNA binding and cleavage studies of Ni(II) complexes with fused aromatic N-containing ligands," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 72, no. 3, pp. 643-647, 2009.

[17] D.-D. Qin, Z.-Y. Yang, and B.-D. Wang, "Spectra and DNAbinding affinities of copper(II), nickel(II) complexes with a novel glycine Schiff base derived from chromone," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 68, no. 3, pp. 912-917, 2007.

[18] B.-D. Wang, Z.-Y. Yang, M.-H. Lu, J. Hai, Q. Wang, and Z. N. Chen, "Synthesis, characterization, cytotoxic activity and DNA binding Ni(II) complex with the 6-hydroxy chromone-3-carbaldehyde thiosemicarbazone," Journal of Organometallic Chemistry, vol. 694, no. 25, pp. 4069-4075, 2009.

[19] Y. Li, Z. Y. Yang, Z. C. Liao, Z. C. Han, and Z. C. Liu, "Synthesis, crystal structure, DNA binding properties and antioxidant activities of transition metal complexes with 3carbaldehyde-chromone semicarbazone," Inorganic Chemistry Communications, vol. 13, no. 10, pp. 1213-1216, 2010.

[20] B.-D. Wang, Z.-Y. Yang, and T.-R. Li, "Synthesis, characterization, and DNA-binding properties of the Ln(III) complexes with 6-hydroxy chromone-3-carbaldehyde-(2;-hydroxy) benzoyl hydrazone," Bioorganic and Medicinal Chemistry, vol. 14, no. 17, pp. 6012-6021, 2006.

[21] P. Kavitha, M. Saritha, and K. L. Reddy, "Synthesis, structural characterization, fluorescence, antimicrobial, antioxidant and DNA cleavage studies of Cu(II) complexes of formyl chromone Schiff bases," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 102, pp. 159-168, 2013.

[22] P. Kavitha, M. R. Chary, B. V A. A. Singavarapu, and K. L. Reddy, "Synthesis, characterization, biological activity and DNA cleavage studies of tridentate Schiff bases and their Co(II) complexes," Journal of Saudi Chemical Society, 2013.

[23] P. Kavitha and K. L. Reddy, "Pd(II) complexes bearing chromone based Schiff bases: synthesis, characterisation and biological activity studies," Arabian Journal of Chemistry, 2012.

[24] A. Nohara, T. Umetani, and Y. Sanno, "A facile synthesis of chromone-3-carboxaldehyde, chromone-3-carboxylic acid and 3-hydroxymethylchromone," Tetrahedron Letters, vol. 14, no. 22, pp. 1995-1998, 1973.

[25] I. Sigg, G. Haas, and T. Winkler, "The reaction of 3formylchromone with ortho-substituted anilines. Preparation of a Tetraaza [14] annulene," Helevetica Chimica Acta, vol. 65, no. 1, pp. 275-279, 1982.

[26] K. M. Khan, N. Ambreen, S. Hussain, S. Perveen, and M. I. Choudhary, "Schiff bases of 3-formylchromone as thymidine phosphorylase inhibitors," Bioorganic and Medicinal Chemistry, vol. 17, no. 8, pp. 2983-2988, 2009.

[27] J. E. Stemper and J. M. Matsen, "Device for turbidity standardizing of cultures for antibiotic sensitivity testing," Applied Microbiology, vol. 19, no. 6, pp. 1015-1016,1970.

[28] K. Shanker, R. Rohini, V. Ravinder, P. M. Reddy, and Y.-P. Ho, "Ru(II) complexes of [N.sub.4] and [N.sub.2][O.sub.2] macrocyclic Schiff base ligands: their antibacterial and antifungal studies," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 73, no. 1, pp. 205-211, 2009.

[29] P. C. Trivedi, Nematode Diseases in Plants, CBS, New Delhi, India, 1st edition, 1998.

[30] J. Cayrol, C. Djian, and L. Pijarowski, "Study of the nematicidal properties of the culture filtrate of the nematophagous fungus Paecilomyces lilacinus," Revue de Nematologie, vol. 12, pp. 331336, 1989.

[31] A. Braca, N. de Tommasi, L. di Bari, C. Pizza, M. Politi, and I. Morelli, "Antioxidant principles from Bauhinia tarapotensis," Journal of Natural Products, vol. 64, no. 7, pp. 892-895, 2001.

[32] S. Sathiyaraj, R. J. Butcher, and Ch. Jayabalakrishnan, "Synthesis, characterization, DNA interaction and in vitro cytotoxicity activities of ruthenium(II) Schiff base complexes," Journal of Molecular Structure, vol. 1030, pp. 95-103, 2012.

[33] W. J. Geary, "The use of conductivity measurements in organic solvents for the characterisation of coordination compounds," Coordination Chemistry Reviews, vol. 7, no. 1, pp. 81-122,1971.

[34] A. I. Vogel, A Text Book of Quantitative Inorganic Analysis, Longman, 3rd edition, 1961.

[35] O. A. El-Gammal, G. A. El-Reash, and S. F. Ahmed, "Structural, spectral, thermal and biological studies on 2-oxo-N;-((4oxo-4H-chromen-3-yl)methylene)-2-(phenylamino)acetohy- drazide (H2L) and its metal complexes," Journal of Molecular Structure, vol. 1007, pp. 1-10, 2012.

[36] C. Anitha, C. D. Sheela, P. Tharmaraj, and S. J. Raja, "Synthesis and characterization of VO(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes of chromone based azo-linked Schiff base ligand," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 98, pp. 35-42, 2012.

[37] M. Padmaja, J. Pragathi, and C. G. Kumari, "Synthesis, spectral characterization, molecular modeling and biological activity of first row transition metal complexes with Schiff base ligand derived from chromone-3-carbaldehyde and o-amino benzoic acid," Journal of Chemical and Pharmaceutical Research, vol. 3, no. 4, pp. 602-613, 2011.

[38] B. Kannamba, K. L. Reddy, and B. V. AppaRao, "Removal of Cu(II) from aqueous solutions using chemically modified chitosan," Journal of Hazardous Materials, vol. 175, no. 1-3, pp. 939-948, 2010.

[39] S. Chandra and L. K. Gupta, "Spectroscopic and biological studies on newly synthesized nickel(II) complexes of semicarbazones and thiosemicarbazones," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 62, no. 4-5, pp. 1089-1094, 2005.

[40] P. K. Singh and D. N. Kumar, "Spectral studies on cobalt(II), nickel(II) and copper(II) complexes of naphthaldehyde substituted aroylhydrazones," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 64, no. 4, pp. 853-858, 2006.

[41] B. E. Warren, X-Ray Diffraction, Dover, New York, NY, USA, 2nd edition, 1990.

[42] X. Huang, Y. Xia, H. Zhang et al., "Synthesis, crystal structure, and fluorescence studies of (1-naphthyl)(pyridyl)urea metal complexes," Inorganic Chemistry Communications, vol. 11, no. 4, pp. 450-453, 2008.

[43] A. K. Sharma and S. Chandra, "Complexation of nitrogen and sulphur donor Schiff's base ligand to Cr(III) and Ni(II) metal ions: synthesis, spectroscopic and antipathogenic studies," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 78, no. 1, pp. 337-342, 2011.

[44] T. A. Yousef, G. M. Abu El-Reash, O. A. El-Gammal, and R. A. Bedier, "Co(II), Cu(II), Cd(II), Fe(III) and U(VI) complexes containing a NSNO donor ligand: synthesis, characterization, optical band gap, in vitro antimicrobial and DNA cleavage studies," Journal of Molecular Structure, vol. 1029, pp. 149-160, 2012.

[45] H.-L. Seng, H.-K. A. Ong, R. N. Z. R. A. Rahman et al., "Factors affecting nucleolytic efficiency of some ternary metal complexes with DNA binding and recognition domains. Crystal and molecular structure of Zn(phen)(edda)," Journal of Inorganic Biochemistry, vol. 102, no. 11, pp. 1997-2011, 2008.

[46] S. K. Bharti, S. K. Patel, G. Nath, R. Tilak, and S. K. Singh, "Synthesis, characterization, DNA cleavage and in vitro antimicrobial activities of copper(II) complexes of Schiff bases containing a 2,4-disubstituted thiazole," Transition Metal Chemistry, vol. 35, no. 8, pp. 917-925, 2010.

[47] D. S. Sigman, A. Mazumder, and D. M. Perrin, "Chemical nucleases," Chemical Reviews, vol. 93, no. 6, pp. 2295-2316,1993.

[48] T. Kobayashi, M. Kunita, S. Nishino et al., "Release of free nucleobases from oligomers by copper(II)-peroxide adduct," Polyhedron, vol. 19, no. 26-27, pp. 2639-2648, 2000.

[49] T. A. Yousef, G. M. Abu El-Reash, O. A. El-Gammal, and R. A. Bedier, "Synthesis, characterization, optical band gap, in vitro antimicrobial activity and DNA cleavage studies of some metal complexes of pyridyl thiosemicarbazone," Journal of Molecular Structure, vol. 1035, pp. 307-317, 2013.

Palakuri Kavitha, K. Laxma Reddy

Department of Chemistry, National Institute of Technology, Warangal 506 004, India Correspondence should be addressed to K. Laxma Reddy; laxmareddychem12@gmail.com

Received 28 October 2013; Accepted 26 March 2014; Published 28 April 2014

Academic Editor: Imre Sovago

TABLE 1: Elemental analysis and physical properties of metal
complexes.

                                                             % found
Molecular formula           Colour                           (cald.)
                            (% yield)     C         H        N

[Ni[([L.sub.1]).sub.2]]     Brick red     64.49     3.21     4.23
[Ni[([C.sub.16][H.sub.10]   (71)          (65.45)   (3.40)   (4.77)
  [O.sub.3]N).sub.2]]
[Ni[([L.sub.2]).sub.2]]     Light green   61.59     3.02     4.21
  x [H.sub.2]O
[Ni[([C.sub.17][H.sub.10]   (62)          (61.75)   (3.32)   (4.24)
  [O.sub.4]N).sub.2] x
  [H.sub.2]O
[Ni[([L.sub.3]).sub.2]]     Brick red     61.07     3.23     9.23
  x [H.sub.2]O
[Ni[([C.sub.15][H.sub.9]    (85)          (61.15)   (3.39)   (9.51)
  [O.sub.3][N.sub.2]).
  sub.2]] x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]     Black         62.21     3.09     4.61
[Ni[([C.sub.16][H.sub.10]   (82)          (62.06)   (3.23)   (4.52)
  [O.sub.2]NS).sub.2]]
[Zn[([L.sub.1]).sub.2]]     Orange        62.91     3.52     4.62
  x [H.sub.2]O
[Zn([C.sub.16][H.sub.10]    (88)          (62.80)   (3.60)   (4.58)
  [O.sub.3][N.sub.2]] x
  [H.sub.2]O
[Zn[([L.sub.2]).sub.2]]     Yellow        62.79     3.15     4.25
[Zn[([C.sub.17][H.sub.10]   (61)          (62.83)   (3.08)   (4.31)
  [O.sub.4]N).sub.2]]
[Zn[([L.sub.3]).sub.2]]     Brick red     60.21     3.25     9.35
[Zn[([C.sub.15][H.sub.9]    (87)          (60.46)   (3.02)   (9.40)
  [O.sub.3][N.sub.2]).
  sub.2]]
[Zn[([L.sub.4]).sub.2]]     Yellow        60.22     3.35     4.21
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]   (73)          (59.68)   (3.41)   (4.35)
  [O.sub.2]NS).sub.2]]
  x [H.sub.2]O

Molecular formula                     M         Molar
                            S         (Ni/Zn)   conductivity
                                                ([Ohm.sup.-1]
                                                [cm.sup.2]
                                                [mol.sup.-1])

[Ni[([L.sub.1]).sub.2]]               9.91      10
[Ni[([C.sub.16][H.sub.10]             (10.00)
  [O.sub.3]N).sub.2]]
[Ni[([L.sub.2]).sub.2]]               8.79      12
  x [H.sub.2]O
[Ni[([C.sub.17][H.sub.10]             (8.88)
  [O.sub.4]N).sub.2] x
  [H.sub.2]O
[Ni[([L.sub.3]).sub.2]]               9.43      15
  x [H.sub.2]O
[Ni[([C.sub.15][H.sub.9]              (9.97)
  [O.sub.3][N.sub.2]).
  sub.2]] x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]     9.30      9.21      14
[Ni[([C.sub.16][H.sub.10]   (10.34)   (9.49)
  [O.sub.2]NS).sub.2]]
[Zn[([L.sub.1]).sub.2]]               10.58     15
  x [H.sub.2]O
[Zn([C.sub.16][H.sub.10]              (10.70)
  [O.sub.3][N.sub.2]] x
  [H.sub.2]O
[Zn[([L.sub.2]).sub.2]]               9.95      11
[Zn[([C.sub.17][H.sub.10]             (10.07)
  [O.sub.4]N).sub.2]]
[Zn[([L.sub.3]).sub.2]]               10.51     18
[Zn[([C.sub.15][H.sub.9]              (10.98)
  [O.sub.3][N.sub.2]).
  sub.2]]
[Zn[([L.sub.4]).sub.2]]     10.01     10.31     20
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]   (9.93)    (10.46)
  [O.sub.2]NS).sub.2]]
  x [H.sub.2]O

TABLE 2: IR spectral data ofligands and their metal complexes
([cm.sup.-1]).

Compound          [nu]   [nu](C=O)   [nu]    [nu](CO)    [nu]
                  (OH)   ([gamma]    (C=N)   (carboxy-   (C-S)
                         pyrone)             late)

[HL.sub.1]        3241   1643        1605
[HL.sub.2]               1651        1605    1365
[HL.sub.3]        3246   1647        1591
[HL.sub.4]               1622        1597                790
[Ni[([L.sub.1])          1619        1563
  .sub.2]]
[Ni[([L.sub.2])          1618        1570    1318
  .sub.2]] x
  [H.sub.2]O
[Ni[([L.sub.3])          1615        1563
  .sub.2]] x
  [H.sub.2]O
[Ni[([L.sub.4])          1598        1564                743
  .sub.2]]
[Zn[([L.sub.1])          1614        1574
  .sub.2]] x
  [H.sub.2]O
[Zn[([L.sub.2])          1615        1563    1347
  .sub.2]]
[Zn[([L.sub.3])          1615        1563
  .sub.2]]
[Zn[([L.sub.4])          1609        1581                751
  .sub.2]] x
  [H.sub.2]O

Compound          [nu]    [nu]
                  (M-N)   (M-O)

[HL.sub.1]
[HL.sub.2]
[HL.sub.3]
[HL.sub.4]
[Ni[([L.sub.1])   467     586
  .sub.2]]
[Ni[([L.sub.2])   419     514
  .sub.2]] x
  [H.sub.2]O
[Ni[([L.sub.3])   480     50
  .sub.2]] x
  [H.sub.2]O
[Ni[([L.sub.4])   443     524
  .sub.2]]
[Zn[([L.sub.1])   460     599
  .sub.2]] x
  [H.sub.2]O
[Zn[([L.sub.2])   480     500
  .sub.2]]
[Zn[([L.sub.3])   488     521
  .sub.2]]
[Zn[([L.sub.4])   441     05
  .sub.2]] x
  [H.sub.2]O

TABLE 3: Electronic, magnetic, and ligand field parameters of Ni(II)
complexes.

Compound                  Absorption      Tentative assignments
                          maxima
                          ([cm.sup.-1])

                          8532            [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.2g](F)
                                          ([[nu].sub.1])
[Ni[([L.sub.1]).sub.2]]   15200           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](F)
                                          ([[nu].sub.2])
                          24900           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](P)
                                          ([[nu].sub.2])
                          8787            [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.2g](F)
                                          ([[nu].sub.1])
[Ni[([L.sub.2]).sub.2]]   16000           [sup.3][A.sub.2g](F)
  x [H.sub.2]O                            [right arrow]
                                          [sup.3][T.sub.1g](F)
                                          ([[nu].sub.2])
                          24390           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](P)
                                          ([[nu].sub.3])
                          8313            [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.2g](F)
                                          ([[nu].sub.1])
[Ni[([L.sub.3]).sub.2]]   14705           [sup.3][A.sub.2g](F)
  x [H.sub.2]O            20833           [right arrow]
                                          [sup.3][T.sub.1g](F)
                                          ([[nu].sub.2])
                          24390           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](P)
                                          ([[nu].sub.3])
                          8628            [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.2g](F)
                                          ([[nu].sub.1])
[Ni[([L.sub.4]).sub.2]]   16313           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](F)
                                          ([[nu].sub.2])
                          24570           [sup.3][A.sub.2g](F)
                                          [right arrow]
                                          [sup.3][T.sub.1g](P)
                                          ([[nu].sub.3])

Compound                  Magnetic   [[nu].sub.2]/   10 Dq
                          moment     [[nu].sub.1]    ([cm.sup.-1])
                          (B.M)

[Ni[([L.sub.1]).sub.2]]   3.12       1.78            8532

[Ni[([L.sub.2]).sub.2]]   3.18       1.82            8787
  x [H.sub.2]O

[Ni[([L.sub.3]).sub.2]]   3.25       1.76            8313
  x [H.sub.2]O

[Ni[([L.sub.4]).sub.2]]   2.91       1.89            8628

Compound                  B              [beta]   LFSE
                          ([cm.sup.-1])           (kJ x
                                                  [mol.sup.-1])

[Ni[([L.sub.1]).sub.2]]   966            0.92     122.50

[Ni[([L.sub.2]).sub.2]]   935            0.89     126.19
  x [H.sub.2]O

[Ni[([L.sub.3]).sub.2]]   943            0.90     119.40
  x [H.sub.2]O

[Ni[([L.sub.4]).sub.2]]   999            0.95     123.92

TABLE 4: Thermal analysis results of metal complexes.

Compound                      Temperature    Found (cald.)
                              ([degrees]C)

[Ni[([L.sub.1]).sub.2]]       180-420        19.38 (18.36)
[Ni[([C.sub.16][H.sub.10]     421-718        68.55 (69.02)
  [O.sub.3]N).sub.2]]
                              >718           12.07 (12.62)
                              30-90          2.83 (2.72)
[Ni[([L.sub.2]).sub.2]]       335-478        60.71 (62.05)
  x [H.sub.2]O
[Ni[([C.sub.17][H.sub.10]     479-849        23.93 (23.61)
  [O.sub.4]N).sub.2]] x
  [H.sub.2]O
                              >849           12.53 (11.62)
[Ni[([L.sub.3]).sub.2]]       30-65          3.09 (2.96)
  x [H.sub.2]O                180-879        83.40 (84.73)
[Ni[([C.sub.15][H.sub.9]      >880           13.51 (12.31)
  [O.sub.3][N.sub.2]).
  sub.2]] x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]       171-410        45.91 (45.25)
[Ni[([C.sub.16][H.sub.10]     411-670        42.14 (42.67)
  [O.sub.2]NS).sub.2]]        >670           11.95 (12.07)
                              30-135         2.45 (2.95)
[Zn[([L.sub.1]).sub.2]]       194-422        24.95 (25.92)
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]     423-790        59.48 (58.09)
  [O.sub.3]N).sub.2]] x       >791           13.12 (13.04)
  [H.sub.2]O
                              195-265        15.55 (16.01)
[Zn[([L.sub.2]).sub.2]]       266-661        69.76 (71.46)
[Zn[([C.sub.17][H.sub.10]     >662           14.69 (12.53)
  [O.sub.4]N).sub.2]]
                              157-192        10.91 (12.93)
[Zn[([L.sub.3]).sub.2]]       193-485        28.65 (29.22)
[Zn[([C.sub.15][H.sub.9]      486-835        46.03 (44.18)
[O.sub.3][N.sub.2]).sub.2]]   >836           14.41 (13.67)
                              30-124         2.41 (2.79)
[Zn[([L.sub.4]).sub.2]]       165-348        27.41 (26.73)
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]     389-632        56.98 (5784)
  [O.sub.2]NS).sub.2]] x      >632           13.20 (12.64)
  [H.sub.2]O

Compound                      Assignment

[Ni[([L.sub.1]).sub.2]]       [C.sub.6][H.sub.4]ON
[Ni[([C.sub.16][H.sub.10]     [C.sub.26][H.sub.16][O.sub.5]N
  [O.sub.3]N).sub.2]]
                              NiO
                              [H.sub.2]O
[Ni[([L.sub.2]).sub.2]]       [C.sub.24][H.sub.14][O.sub.5][N.sub.2]
  x [H.sub.2]O
[Ni[([C.sub.17][H.sub.10]     [C.sub.10][H.sub.6][O.sub.2]
  [O.sub.4]N).sub.2]] x
  [H.sub.2]O
                              NiO
[Ni[([L.sub.3]).sub.2]]       [H.sub.2]O
  x [H.sub.2]O                [C.sub.30][H.sub.18][O.sub.5][N.sub.4]
[Ni[([C.sub.15][H.sub.9]      NiO
  [O.sub.3][N.sub.2]).
  sub.2]] x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]       [C.sub.16][H.sub.10][O.sub.2]NS
[Ni[([C.sub.16][H.sub.10]     [C.sub.16][H.sub.10]ONS
  [O.sub.2]NS).sub.2]]        NiO
                              [H.sub.2]O
[Zn[([L.sub.1]).sub.2]]       [C.sub.10][H.sub.6][O.sub.2]
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]     [C.sub.22][H.sub.14][O.sub.3][N.sub.2]
  [O.sub.3]N).sub.2]] x       ZnO
  [H.sub.2]O
                              [C.sub.7][H.sub.4]O
[Zn[([L.sub.2]).sub.2]]       [C.sub.27][H.sub.16][O.sub.4][N.sub.2]
[Zn[([C.sub.17][H.sub.10]     ZnO
  [O.sub.4]N).sub.2]]
                              [C.sub.5][H.sub.3]N
[Zn[([L.sub.3]).sub.2]]       [C.sub.10][H.sub.6][O.sub.2]N
[Zn[([C.sub.15][H.sub.9]      [C.sub.15][H.sub.9][O.sub.3][N.sub.2]
[O.sub.3][N.sub.2]).sub.2]]   ZnO
                              [H.sub.2]O
[Zn[([L.sub.4]).sub.2]]       [C.sub.10][H.sub.6][O.sub.2]N
  x [H.sub.2]O
[Zn[([C.sub.16][H.sub.10]     [C.sub.22][H.sub.14]ON[S.sub.2]
  [O.sub.2]NS).sub.2]] x      ZnO
  [H.sub.2]O

TABLE 5: Observed and calculated powder XRD patterns of (a)
[Ni[([L.sub.1]).sub.2]] (b) [Zn[([L.sub.1]).sub.2]] x [H.sub.2]O.

(a)

S.       20                [delta]    d-spacing         h    k    l
number   Obser-   Calcu-   2[theta]   Obser-   Calcu-
         ved      lated               ved      lated

1        10.57    10.57    0          8.3627   8.3627   0    1    0
2        11.29    11.29    0          7.8314   7.8314   1    0    0
3        13.44    13.44    0          6.5805   6.5805   0    0    1
4        14.79    14.79    0          5.9847   5.9847   -1   1    0
5        15.75    15.75    0          5.6205   5.6205   -1   -1   1
6        17.79    17.79    0          4.9805   4.9805   -1   1    1
7        18.85    18.68    0.164      4.7046   4.7455   0    1    1
8        21.16    21.22    -0.06      4.1962   4.1845   1    0    1
9        22.14    22.06    0.074      4.0121   4.0255   1    -1   1
10       24.05    24.07    -0.013     3.6968   3.6948   -1   0    2
11       25.04    24.99    0.054      3.5533   3.5608   1    2    0
12       26.33    26.35    -0.017     3.382    3.3799   -1   2    1
13       28.1     28.04    0.061      3.1731   3.1799   -1   1    2
14       32.65    32.65    0          2.7404   2.7405   2    2    0
15       35.06    35.07    -0.012     2.5575   2.5566   -3   1    0
16       38.92    38.86    0.054      2.3124   2.3155   -2   3    1
17       43.89    43.95    -0.058     2.0612   2.0586   -1   3    2
18       45.13    45.16    -0.033     2.0076   2.0062   -2   -3   3
(b)
S.       20 values         [delta]    d-spacing         h    k    i
number   Obser-   Calcu-   2[theta]   Obser-   Calcu-
         ved      lated               ved      lated

1        12.58    12.58    0          7.0315   7.0315   1    1    0
2        13.81    13.81    0          6.4077   6.4077   -1   0    1
3        15.73    15.73    0          5.6299   5.6299   1    0    1
4        17.35    17.35    0          5.1064   5.1064   -1   1    1
5        20.75    20.77    -0.017     4.2777   4.2742   -1   3    0
6        24.09    24.13    -0.031     3.6907   3.6859   -1   -3   2
7        25.32    25.31    0.012      3.5141   3.5158   2    2    0
8        27.93    27.97    -0.038     3.1916   3.1873   -1   -4   2
9        30.15    30.16    -0.008     2.9620   2.9612   0    -3   3
10       31.92    31.90    0.021      2.8015   2.8033   2    -5   2
11       34.43    34.45    -0.017     2.6028   2.6016   -1   5    0
12       36.05    36.06    -0.008     2.4892   2.4886   -1   0    3
13       42.75    42.83    -0.081     2.1137   2.1099   3    1    2

TABLE 6: MIC values of antimicrobial activity of ligands and their
metal complexes ([micro]g/mL).

Compound                  Bacillus   Staphylococcus   Proteus
                          subtilis   aureus           vulgaris

[HL.sub.1]                -          -                -
[HL.sub.2]                80         80               80
[HL.sub.3]                -          -                -
[HL.sub.4]                -          -                -
[Ni[([L.sub.1]).sub.2]]   35         40               32
[Ni[([L.sub.2]).sub.2]]   70         80               65
  x [H.sub.2]O
[Ni[([L.sub.3]).sub.2]]   45         45               50
  x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]   75         80               -
[Zn[([L.sub.1]).sub.2]]   -          -                -
  x [H.sub.2]O
[Zn[([L.sub.2]).sub.2]]   85         78               80
[Zn[([L.sub.3]).sub.2])   30         30               33
[Zn[([L.sub.4]).sub.2]]   -          80               -
  x [H.sub.2]O
Kanamycin                 4          10               8
Clotrimazole              -          -                -

Compound                  Klebsiella   Candida
                          pneumoniae   albicans

[HL.sub.1]                -            -
[HL.sub.2]                80           80
[HL.sub.3]                -            -
[HL.sub.4]                -            -
[Ni[([L.sub.1]).sub.2]]   41           75
[Ni[([L.sub.2]).sub.2]]   85           -
  x [H.sub.2]O
[Ni[([L.sub.3]).sub.2]]   33           33
  x [H.sub.2]O
[Ni[([L.sub.4]).sub.2]]   78           -
[Zn[([L.sub.1]).sub.2]]   -            -
  x [H.sub.2]O
[Zn[([L.sub.2]).sub.2]]   75           80
[Zn[([L.sub.3]).sub.2])   30           33
[Zn[([L.sub.4]).sub.2]]   80           -
  x [H.sub.2]O
Kanamycin                 11           -
Clotrimazole              -            10

TABLE 7: [IC.sub.50] values ([micro]g/mL) of DPPH radical
scavenging activity of ligands and their metal complexes.

Compound                  [IC.sub.50]
                          ([micro]g/mL)

[HL.sub.3]                1.27
[HL.sub.4]                0.40
[Ni[([L.sub.1]).sub.2]]   1.21
[Ni[([L.sub.4]).sub.2]]   1.09
[Zn[([L.sub.4]).sub.2]]   0.69
  x [H.sub.2]O
BHT                       0.67

TABLE 8: [IC.sub.50] values ([micro]g/mL) of cytotoxic activity
of ligands and their metal complexes.

Compound                               Raw     MCF-7   COLO 205

[HL.sub.1]                             46.8    24.5    20.1
[HL.sub.2]                             56.1    34.2    39.1
[HL.sub.3]                             52.8    29.2    15.2
[HL.sub.4]                             46.9    30.4    68.1
[N1[([L.sub.1]).sub.2]]                224.8   67.1    54.6
[Ni[([L.sub.2]).sub.2]] x [H.sub.2]O   36.3    26.5    60.9
[Ni[([L.sub.3]).sub.2]] x [H.sub.2]O   53.0    36.9    71.4
[Ni[([L.sub.4]).sub.2]]                58.6    35.6    49.9
[Zn[([L.sub.1]).sub.2]] x [H.sub.2]O   44.0    40.1    54.7
[Zn[([L.sub.2]).sub.2]]                34.0    52.3    43.9
[Zn[([L.sub.3]).sub.2]                 33.1    22.6    42.0
[Zn[([L.sub.4]).sub.2]] x [H.sub.2]O   42.5    39.2    53.5
Cis-platin                             1.5     1.7     5.6
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Kavitha, Palakuri; Reddy, K. Laxma
Publication:Bioinorganic Chemistry and Applications
Article Type:Report
Date:Jan 1, 2014
Words:10112
Previous Article:Electron paramagnetic resonance study of thermally treated bismuth subgallate.
Next Article:In vitro antibacterial activity and mechanism of silver nanoparticles against foodborne pathogens.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters